CJC-1295 (no DAC) / Ipamorelin Protocol
Mod GRF 1-29 + Ipamorelin | Pulsatile Growth Hormone Optimization
On this page
What is CJC-1295 (no DAC) / Ipamorelin Protocol?
The CJC-1295 (no DAC)/Ipamorelin protocol pairs two short-acting growth-hormone-research peptides that scientists often study together: CJC-1295 signals the pituitary through one receptor pathway, and Ipamorelin signals it through a different one, producing a pulsatile release pattern similar to the body's own. It's a combination researchers use in study designs rather than a single approved compound. Both peptides in this protocol are sold here strictly as research chemicals for laboratory study, not for use in people or animals.
Key terms:
CJC-1295 (no DAC) / Ipamorelin Protocol is a combination protocol (ghrh analog + ghrp).
This research protocol pairs two peptides that act through different receptors. CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life of 30 minutes to 2 hours, so growth hormone comes out in bursts, much like the body's own rhythm. Ipamorelin prompts growth hormone release on its own pathway, without changing cortisol, ACTH, or prolactin. Note: this protocol uses the no-DAC version on purpose, because the pattern being studied is a pulsatile release.
Key research areas
- Dual-pathway GH optimization through complementary mechanisms
- Short half-lives (30 min-2 hours) produce synergistic pulsatile GH spikes
- Mimics natural physiology without cortisol effects
Researched dosing
This table reflects how researchers have structured study designs combining CJC-1295 and Ipamorelin — dose ranges and schedules presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| General health studies | 200 mcg each (0.2mL if 1mg/mL) | Once daily before bed | SubQ |
| GH-pulsatility studies | 100-150 mcg each (0.1-0.15mL if 1mg/mL) | Twice daily (AM + before bed) | SubQ |
| Performance studies | 250 mcg each (0.25mL if 1mg/mL) | Once daily before bed | SubQ |
| Recovery studies | 300 mcg each (0.3mL if 1mg/mL) | Once daily before bed | SubQ |
| Lower-dose studies | 150 mcg each (0.15mL if 1mg/mL) | 5 days per week | SubQ |
Commonly cycled 12 weeks on, 4+ weeks off.
How it works
At the cell level, this protocol's research looks at how CJC-1295 activates GHRH receptors while Ipamorelin activates a separate ghrelin-mimicking receptor — two different signaling routes that both end in pituitary growth-hormone release.
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on pituitary somatotrophs, triggering cAMP/PKA-mediated GH synthesis with a short 30-minute to 2-hour half-life. Ipamorelin selectively activates ghrelin receptors (GHSR1a) via Gq/11-linked calcium signaling without affecting ACTH or cortisol pathways. Together, the dual-pathway activation produces amplified, pulsatile GH spikes. Note: Combination benefits are theoretically sound but lack direct clinical validation.
Research applications
This section lists the research areas scientists have studied for this combination protocol — a summary of what's been proposed in the literature, not medical claims about people; the combination itself lacks dedicated clinical trials of its own.
Muscle Development
Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training. Sustained GH patterns may accelerate muscle repair between exercise sessions. GH optimization helps maintain muscle during caloric restriction or aging.
Metabolic Health
Dual-pathway GH optimization improves metabolic function through enhanced growth hormone pulsatility.
Longevity
GH optimization supports longevity benefits through enhanced recovery, body composition, and tissue repair.
Recovery
Enhanced growth hormone patterns support recovery from exercise and injury through improved protein synthesis and tissue repair.
Dosage reference
- Doses used in research
- 200–250 mcg of each peptide once daily, or 100–150 mcg of each twice daily
- Frequency in studies
- Once daily before bed, or twice daily (AM + before bed) for enhanced pulsatility
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Sleep improvements: 1-2 weeks. Recovery benefits: 2-4 weeks. Body composition: 6-12 weeks
- Storage
- Refrigerate reconstituted peptides at 2-8°C. Use within 30 days of reconstitution for optimal potency
- Cycle length
- Literature references 8-12 week study windows separated by ~4-week intervals to maintain receptor sensitivity
- Break between cycles
- 4 week minimum breaks help preserve natural GH production and receptor responsiveness
Interactions
This list shows which other compounds are studied alongside this protocol, and why — since it's already a two-peptide combination, added caution applies to any further stacking.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried CJC-1295 and Ipamorelin powder into liquid research solutions, whether supplied as a single blended vial or two separate ones.
- Allow vial(s) to reach room temperature (15-20 minutes)
- Clean vial top(s) with alcohol swab and allow to dry
- Calculate required bacteriostatic water volume using the calculator below
- Draw calculated volume of bacteriostatic water into syringe
- Inject water slowly down the inside wall of the vial (never directly onto powder)
- Gently swirl until powder completely dissolves (never shake)
- Solution should be clear - discard if cloudy or contains particles
Lyophilized: Room temperature until reconstitution, use within As per manufacturer dating
Reconstituted: 2-8°C, use within 30 days
Open the CJC-1295 / Ipamorelin Protocol reconstitution calculatorQuality indicators
These are the checks researchers use to confirm a blended or paired CJC-1295/Ipamorelin sample is pure and correctly identified before it's used in a study.
Standard format labeling - Most common: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin' for blended vials, or separate 5mg vials for individual peptides
Format selection guidance - BEGINNERS: Separate vials allow individual tolerance testing. EXPERIENCED: Blended offers convenience but limits dose adjustment
1:1 ratio maintenance - Whether blended or separate, equal amounts of each peptide are recommended for optimal complementary effects
Clear reconstitution - Both formats should dissolve completely clear without particles, cloudiness, or precipitation
Certificate of Analysis - Reputable sources provide COA with purity testing. For blends, should show individual peptide purities
Proper cold chain - Should arrive with cold packs and require immediate refrigeration. Temperature stability is critical
Poor storage indicators - Avoid products with damaged packaging, missing refrigeration, or exposure to heat during shipping
Research limitations - Note: Combination protocols lack peer-reviewed clinical validation compared to individual peptide studies
DAC vs No-DAC clarity - Ensure product is labeled 'CJC-1295 no DAC' or 'Mod GRF 1-29'. The DAC version has different pharmacokinetics (6-8 day vs 30-min half-life) and is NOT interchangeable in this protocol
What to expect
This timeline reflects what the research literature and preclinical data report at each study stage for the individual peptides — research context for comparing studies, not a personal-results promise, since the combination itself hasn't been directly studied clinically.
Improved sleep depth and quality. Some users report more vivid dreams
Enhanced recovery from exercise. Reduced muscle soreness and improved energy
Gradual body composition changes. Improved skin quality and general well-being
Optimized benefits if protocol is effective. Individual responses vary significantly
Some benefits may persist for several weeks due to improved sleep and recovery patterns
Safety notes
This section covers handling cautions and regulatory notes for this protocol — research-use-only scope for both peptides, not medical safety advice for people.
- Test individual peptides separately before using blended protocols if possible
- Monitor blood glucose if diabetic - growth hormone can affect insulin sensitivity
- Start with conservative doses (200mcg each) to assess individual tolerance
- Maintain injection site rotation to prevent lipodystrophy or tissue damage
- Regular bloodwork recommended to monitor IGF-1 levels and overall health markers
- No clinical trials have validated specific combination benefits or safety profiles
- Use only pharmaceutical-grade peptides with verified certificates of analysis
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Note: This landmark study used CJC-1295 WITH DAC (5.8-8.1 day half-life), not the no-DAC version used in CJC/IPA protocols. Included for reference on the GHRH analog mechanism, but pharmacokinetics differ significantly from Mod GRF 1-29.
CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes to 2 hours due to lack of albumin-binding DAC. This short duration enables pulsatile GH release patterns preferred for combination protocols with GHRPs like Ipamorelin.
Demonstrated CJC-1295 preserves pulsatile GH secretion while increasing basal levels 7.5-fold.